Antithrombotic effect of NTPDase1/CD39

NTPDase1/CD39的抗血栓作用

• 批准号: nhmrc : 344801
• 负责人: Prof Anthony D'Apice
• 金额: $ 24.62万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/antithrombotic-effect-ntpdase1cd39/98367
• 关键词: Antithrombotic; effect; NTPDase1; CD39

The prevalence of heart disease and stroke is increasing in the affluent world. These disorders are due to a narrowing of arteries due to clot formation, thereby reducing available blood supply to the heart and brain. Blood vessel occlusion is due a combination of clot formation initiated by platelet clumping, and inflammation surrounding the vessel wall. Drugs that prevent the clumping of platelets on the inner lining of the blood vessels play an important role in the prevention and treatment of heart attack and stroke. The currently available drugs are not universally effective and their use is often limited by adverse reactions. In this submission, we propose to investigate the efficiency of a new drug that will prevent clot formation and will also tackle inflammation. This drug is a derivative of an enzyme that is already present on platelets and cells that line blood vessels. We have modified this enzyme in a manner that will increase the enzyme activity on the surface of platelets and on the cells that line the blood vessel wall. We will thoroughly study this new drug by performing experiments in the laboratory as well as by studying its effect in mice.

在富裕的世界里，心脏病和中风的患病率正在增加。这些疾病是由于血栓形成导致动脉狭窄，从而减少了心脏和大脑的可用血液供应。血管闭塞是由血小板聚集引起的凝块形成和血管壁周围的炎症共同作用的结果。防止血小板聚集在血管内层的药物在预防和治疗心脏病发作和中风方面发挥着重要作用。目前可用的药物并不是普遍有效的，它们的使用往往受到不良反应的限制。在这份意见书中，我们建议调查一种新药的效率，这种新药将防止血栓形成，并将治疗炎症。这种药物是一种酶的衍生物，这种酶已经存在于血小板和血管内皮细胞上。我们已经对这种酶进行了修饰，以增加血小板表面和血管壁细胞上的酶活性。我们将通过在实验室进行实验以及在小鼠身上研究其效果来深入研究这种新药。